Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
An article available online in Cancer makes the rather surprising suggestion that high serum levels of 17β-estradiol (E2) may be better indicators of risk for high-grade prostate cancer than high serum levels of testosterone.
Filed under: Diagnosis, Management, Risk | Tagged: 7β-estradiol, grade, risk, testosterone | 1 Comment »
An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: LHRH agonist, long-acting, recovery, serum, short-acting, testosterone | 2 Comments »
An article in the May issue of BJU International has proposed establishment of an international data registry as being “the quickest way” to establish basic data on the risks related to testosterone replacement therapy in men with untreated prostate cancer.
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: hypogonadism, risk, serum, T, testosterone | Leave a Comment »
It is becoming increasingly clear that the prevention, treatment, and management of prostate cancer is at an intellectual as well as a practical, clinical crossroads.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: dutasteride, finasteride, Prevention, PSA, screening, supplement, testing, testosterone | 2 Comments »
First-line androgen deprivation therapy (ADT) for a man with metastatic prostate cancer has long been been either surgical or medical castration. In the case of medical castatration, the form of medication most commonly used since the mid to late 1980s has been an LHRH agonist (e.g., leuprolide acetate).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, LHRH, suppression, testosterone | 2 Comments »
One of the most controversial issues in the management of prostate cancer is whether testosterone therapy can be given to men who have or are at risk for the recurrence of this type of cancer. Such use of testosterone therapy has been contraindicated for many years, but recent data has started to question this longstanding [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: deficiency, progression, risk, supplement, testosterone | 5 Comments »
A new paper from a research team in Seattle probably has limited relevance to our understanding of the real risks associated with androgen supplementation and subequent diagnosis of prostate cancer (or other prostate disorders) — even though it was a randomized, double-blind clinical trial.
Filed under: Diagnosis, Prevention, Risk | Tagged: androgen, DHT, dihydrotestosterone, risk, testosterone | Leave a Comment »
A few weeks ago, a Letter to the Editor in the New England Journal of Medicine focused on the significance of castrate levels of serum testosterone (serum T) in men being treated with LHRH agonists for advanced forms of prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, serum, survival, T, testosterone | 3 Comments »
A new study by a French research team has suggested that there may be a prognostic relationship between the pretreatment testosterone (T) level and the post-surgical pathology of men who undergo radical prostatectomy (RP) for treatment of localized prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: pathology, radical prostatectomy, T, testosterone | 2 Comments »
According to a media release issued just before Thanksgiving, the FDA has approved a new formulation of testosterone supplement (originally developed by an Australian company called Acrux) and licensed to Eli Lilly & Co. for marketing in the USA and the rest of the world.
Filed under: Living with Prostate Cancer | Tagged: Axiron, supplement, testosterone, underarm | 2 Comments »
Ever since it was recognized that there might be an association between taking statins (as a preventive treatment for elevated cholesterol levels) and risk for prostate cancer (which is now disputed), there has been an associated question as to whether men taking statins generally had a lower PSA level than men who were not, and [...]
Filed under: Diagnosis, Prevention, Risk | Tagged: cholesterol, PSA, risk, statin, testosterone | 1 Comment »
A paper in a forthcoming issue of European Urology recommends strongly that clinicians should monitor serum testosterone (serum T) levels during androgen-deprivation therapy (ADT) in men with prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, serum, serum T, testosterone | 2 Comments »
… an underarm roll-on … and it’s a proposed new way to provide prescription-grade testosterone replacement therapy for men with low testosterone levels (hypogonadism).
Filed under: Drugs in development | Tagged: replacement therapy, roll-on, testosterone | Leave a Comment »
While it has never been categorically proven that adding an oral antiandrogen like flutamide or bicalutamide (Casodex) to injections of LHRH agonists (e.g., leuprolide actetate) improves overall patient survival, there had been little doubt in people’s minds that giving an antiandrogen for a week or two before a first LHRH agonist injection prevented the problem [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, flare, LHRH agonist, testosterone | 1 Comment »
There have been a number of interesting reports over the past couple of days that are summarized briefly below. They encompass such topics as: The validity of the Epstein criteria in predicting clinically indolent prostate cancer MRI and MRSI in patient work-up prior to treatment for stage T1c disease Contrast-enhanced, color Döppler ultrasound and prostate [...]
Filed under: Uncategorized | Tagged: ADT, age, androgen deprivation therapy, color Döppler, comorbidities, Epsetin criteria, Gleason score, magnetic resonance, mortality, MRI, MRSI, testosterone, ultrasound, unilateral | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site